Literature DB >> 8739083

A fibroadenoma with a t(4;12) (q27;q15) affecting the HMGI-C gene, a member of the high mobility group protein gene family.

B Staats1, U Bonk, S Wanschura, P Hanisch, E F Schoenmakers, W J Van de Ven, S Bartnitzke, J Bullerdiek.   

Abstract

An intracanalicular fibroadenoma of the breast showing a clonal chromosomal aberration t(4;12) (q27;q15) as the sole cytogenetic abnormality is described. In order to narrow down the breakpoint region on chromosome 12 on the molecular level we performed fluorescence in situ hybridization (FISH) analysis with a cosmid pool originating from a YAC-contig overspanning part of the region 12q14-15. We were able to narrow down the breakpoint to an approximately 230kb fragment belonging to the HMGI-C gene which maps within an area recently designated as MAR (Multiple Aberration Region). The chromosomal breakpoints of other frequent benign solid tumors, i.e. lipomas, uterine leiomyomas, and pleomorphic adenomas are clustered within the third intron of that gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739083     DOI: 10.1007/bf01806149

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  31 in total

1.  Involvement of the long arm of chromosome 12 in chromosome rearrangements of uterine leiomyoma.

Authors:  R Vanni; U Lecca
Journal:  Cancer Genet Cytogenet       Date:  1988-05

2.  Rearrangements of chromosome region 12q13----q15 in pleomorphic adenomas of the human salivary gland (PSA).

Authors:  J Bullerdiek; S Bartnitzke; M Weinberg; R Chilla; J Haubrich; W Schloot
Journal:  Cytogenet Cell Genet       Date:  1987

3.  Characteristic chromosome abnormalities, including rearrangements of 6p, del(7q), +12, and t(12;14), in 44 uterine leiomyomas.

Authors:  M Nilbert; S Heim; N Mandahl; U M Flodérus; H Willén; F Mitelman
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

4.  Fibroadenoma of the breast showing a translocation (6;14), a ring chromosome and two markers involving parts of chromosome 11.

Authors:  E Leuschner; K Meyer-Bolte; J Caselitz; S Bartnitzke; J Bullerdiek
Journal:  Cancer Genet Cytogenet       Date:  1994-09

5.  Clonal analysis of fibroadenoma and phyllodes tumor of the breast.

Authors:  S Noguchi; K Motomura; H Inaji; S Imaoka; H Koyama
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

6.  Regional fine mapping of the multiple-aberration region involved in uterine leiomyoma, lipoma, and pleomorphic adenoma of the salivary gland to 12q15.

Authors:  S Wanschura; B Kazmierczak; E Schoenmakers; E Meyen; S Bartnitzke; W Van de Ven; J Bullerdiek; W Schloot
Journal:  Genes Chromosomes Cancer       Date:  1995-09       Impact factor: 5.006

7.  Trisomy 8 as a recurrent clonal abnormality in breast cancer?

Authors:  J Bullerdiek; E Leuschner; E Taquia; U Bonk; S Bartnitzke
Journal:  Cancer Genet Cytogenet       Date:  1993-01

8.  Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas.

Authors:  N Mandahl; S Heim; K Arheden; A Rydholm; H Willén; F Mitelman
Journal:  Hum Genet       Date:  1988-07       Impact factor: 4.132

9.  Molecular characterization of MAR, a multiple aberration region on human chromosome segment 12q13-q15 implicated in various solid tumors.

Authors:  W J Van de Ven; E F Schoenmakers; S Wanschura; B Kazmierczak; P F Kools; J M Geurts; S Bartnitzke; H Van den Berghe; J Bullerdiek
Journal:  Genes Chromosomes Cancer       Date:  1995-04       Impact factor: 5.006

10.  Identification, molecular cloning, and characterization of the chromosome 12 breakpoint cluster region of uterine leiomyomas.

Authors:  E F Schoenmakers; R Mols; S Wanschura; P F Kools; J M Geurts; S Bartnitzke; J Bullerdiek; H van den Berghe; W J Van de Ven
Journal:  Genes Chromosomes Cancer       Date:  1994-10       Impact factor: 5.006

View more
  8 in total

1.  Hmga2 is dispensable for cutaneous squamous cell carcinoma.

Authors:  Andrew White; Aimee Flores; Jessica Ong; William E Lowry
Journal:  Exp Dermatol       Date:  2016-05       Impact factor: 3.960

2.  HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors.

Authors:  P Rogalla; K Drechsler; G Frey; Y Hennig; B Helmke; U Bonk; J Bullerdiek
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

3.  HMGA2 expression in white adipose tissue linking cellular senescence with diabetes.

Authors:  Dominique Nadine Markowski; Helge Wilhelm Thies; Andrea Gottlieb; Heiner Wenk; Manfred Wischnewsky; Jörn Bullerdiek
Journal:  Genes Nutr       Date:  2013-07-24       Impact factor: 5.523

Review 4.  Human breast development.

Authors:  B A Howard; B A Gusterson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-04       Impact factor: 2.673

Review 5.  Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids.

Authors:  Burkhard Helmke; Joern Bullerdiek; Carsten Holzmann; Wolfgang Kuepker; Birgit Rommel
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

6.  Intravenous leiomyomatosis: an unusual intermediate between benign and malignant uterine smooth muscle tumors.

Authors:  Zehra Ordulu; Marisa R Nucci; Paola Dal Cin; Monica L Hollowell; Christopher N Otis; Jason L Hornick; Peter J Park; Tae-Min Kim; Bradley J Quade; Cynthia C Morton
Journal:  Mod Pathol       Date:  2016-02-19       Impact factor: 7.842

7.  Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer.

Authors:  C Langelotz; P Schmid; C Jakob; U Heider; K D Wernecke; K Possinger; O Sezer
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

8.  Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast.

Authors:  Piotr Ziółkowski; Elzbieta Gamian; Beata Osiecka; Alexandre Zougman; Jacek R Wiśniewski
Journal:  J Biomed Biotechnol       Date:  2009-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.